Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation
Introduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, inte...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Kourosh Sayehmiri [verfasserIn] Kamran Alimoghaddam [verfasserIn] Ardeshir Ghavamzadeh [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2010 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: International Journal of Hematology-Oncology and Stem Cell Research - Tehran University of Medical Sciences, 2020, 4(2010), 2 |
|---|---|
| Übergeordnetes Werk: |
volume:4 ; year:2010 ; number:2 |
| Links: |
|---|
| Katalog-ID: |
DOAJ023673206 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ023673206 | ||
| 003 | DE-627 | ||
| 005 | 20230307065856.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2010 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ023673206 | ||
| 035 | |a (DE-599)DOAJ9ec6998aa0c14cefb1047830d6430628 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a Kourosh Sayehmiri |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, intensification of therapy by the use of high-dose Cytarabine allogeneic stem cell transplantation in selected cases, paralleled by improvement in supportive care may have contributed to the impotent. In this article we use parametric survival models for recognizing prognostic factors in acute leukemia patients. Patients and methods: Data on patients who underwent bone marrow or peripheral blood transplantation were obtained from the Hematology- Oncology and bone marrow transplantation research center at Shariati hospital, Tehran, Iran. Transplantations were performed between Oct. 17, 1993 to Jan. 31, 2007. Written informed consents for hematopoietic cell collection and transplantation were obtained from patients and donors. The study included patients 2 to 56 years of age who had received either an HLA-matched marrow transplant or a marrow transplant with a single HLA mismatch from an unrelated donor. The mean follow- up period was about 2 years after transplantation. Results: Five hundred and seven patients were included in the study. There were 301 with acute myeloid leukemia (AML) and 206 with acute lymphoblastic leukemia (ALL). The median ages of the AML and ALL patients were 27 (2-55) and 20 years (2-52), respectively. In ALL patients, Prior viral exposure- cytomegalovirus antibody was positive in 143 patients and negative in 30 patients. In AML patients’ Prior viral exposure- cytomegalovirus antibody was positive in 220 patients and negative in 41patients. Table- 1 shows the characteristics of 507 patients who included in the study. Conclusion: In spite of no significant difference in follow-up time, serological status (CMV), donor-recipients sex match, bone marrow cell dose(WBC, CD34, MNC), donor type, source of stem cell, graft type, and conditioning regimen, (Busulfan- Oral, Cyclophosphamide, ALG/AIS/ATG, Stoposide)(Table- 1) in both AML and ALL patients, generalized gamma distribution shows that the mean of SBMT in AML patients is 2.52 times of ALL patients. | ||
| 650 | 4 | |a AML | |
| 650 | 4 | |a ALL | |
| 650 | 4 | |a Prognostic Factor | |
| 650 | 4 | |a Death Hazard Function | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a Kamran Alimoghaddam |e verfasserin |4 aut | |
| 700 | 0 | |a Ardeshir Ghavamzadeh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Hematology-Oncology and Stem Cell Research |d Tehran University of Medical Sciences, 2020 |g 4(2010), 2 |w (DE-627)688077250 |w (DE-600)2652853-8 |x 20082207 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2010 |g number:2 |
| 856 | 4 | 0 | |u https://doaj.org/article/9ec6998aa0c14cefb1047830d6430628 |z kostenfrei |
| 856 | 4 | 0 | |u https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/244 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2008-2207 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2010 |e 2 | ||
| author_variant |
k s ks k a ka a g ag |
|---|---|
| matchkey_str |
article:20082207:2010----::oprsnfrgotcatradethzrfntooaueylilueialnaueypolsilueial |
| hierarchy_sort_str |
2010 |
| callnumber-subject-code |
RC |
| publishDate |
2010 |
| allfields |
(DE-627)DOAJ023673206 (DE-599)DOAJ9ec6998aa0c14cefb1047830d6430628 DE-627 ger DE-627 rakwb eng RC254-282 Kourosh Sayehmiri verfasserin aut Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, intensification of therapy by the use of high-dose Cytarabine allogeneic stem cell transplantation in selected cases, paralleled by improvement in supportive care may have contributed to the impotent. In this article we use parametric survival models for recognizing prognostic factors in acute leukemia patients. Patients and methods: Data on patients who underwent bone marrow or peripheral blood transplantation were obtained from the Hematology- Oncology and bone marrow transplantation research center at Shariati hospital, Tehran, Iran. Transplantations were performed between Oct. 17, 1993 to Jan. 31, 2007. Written informed consents for hematopoietic cell collection and transplantation were obtained from patients and donors. The study included patients 2 to 56 years of age who had received either an HLA-matched marrow transplant or a marrow transplant with a single HLA mismatch from an unrelated donor. The mean follow- up period was about 2 years after transplantation. Results: Five hundred and seven patients were included in the study. There were 301 with acute myeloid leukemia (AML) and 206 with acute lymphoblastic leukemia (ALL). The median ages of the AML and ALL patients were 27 (2-55) and 20 years (2-52), respectively. In ALL patients, Prior viral exposure- cytomegalovirus antibody was positive in 143 patients and negative in 30 patients. In AML patients’ Prior viral exposure- cytomegalovirus antibody was positive in 220 patients and negative in 41patients. Table- 1 shows the characteristics of 507 patients who included in the study. Conclusion: In spite of no significant difference in follow-up time, serological status (CMV), donor-recipients sex match, bone marrow cell dose(WBC, CD34, MNC), donor type, source of stem cell, graft type, and conditioning regimen, (Busulfan- Oral, Cyclophosphamide, ALG/AIS/ATG, Stoposide)(Table- 1) in both AML and ALL patients, generalized gamma distribution shows that the mean of SBMT in AML patients is 2.52 times of ALL patients. AML ALL Prognostic Factor Death Hazard Function Neoplasms. Tumors. Oncology. Including cancer and carcinogens Kamran Alimoghaddam verfasserin aut Ardeshir Ghavamzadeh verfasserin aut In International Journal of Hematology-Oncology and Stem Cell Research Tehran University of Medical Sciences, 2020 4(2010), 2 (DE-627)688077250 (DE-600)2652853-8 20082207 nnns volume:4 year:2010 number:2 https://doaj.org/article/9ec6998aa0c14cefb1047830d6430628 kostenfrei https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/244 kostenfrei https://doaj.org/toc/2008-2207 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2010 2 |
| spelling |
(DE-627)DOAJ023673206 (DE-599)DOAJ9ec6998aa0c14cefb1047830d6430628 DE-627 ger DE-627 rakwb eng RC254-282 Kourosh Sayehmiri verfasserin aut Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, intensification of therapy by the use of high-dose Cytarabine allogeneic stem cell transplantation in selected cases, paralleled by improvement in supportive care may have contributed to the impotent. In this article we use parametric survival models for recognizing prognostic factors in acute leukemia patients. Patients and methods: Data on patients who underwent bone marrow or peripheral blood transplantation were obtained from the Hematology- Oncology and bone marrow transplantation research center at Shariati hospital, Tehran, Iran. Transplantations were performed between Oct. 17, 1993 to Jan. 31, 2007. Written informed consents for hematopoietic cell collection and transplantation were obtained from patients and donors. The study included patients 2 to 56 years of age who had received either an HLA-matched marrow transplant or a marrow transplant with a single HLA mismatch from an unrelated donor. The mean follow- up period was about 2 years after transplantation. Results: Five hundred and seven patients were included in the study. There were 301 with acute myeloid leukemia (AML) and 206 with acute lymphoblastic leukemia (ALL). The median ages of the AML and ALL patients were 27 (2-55) and 20 years (2-52), respectively. In ALL patients, Prior viral exposure- cytomegalovirus antibody was positive in 143 patients and negative in 30 patients. In AML patients’ Prior viral exposure- cytomegalovirus antibody was positive in 220 patients and negative in 41patients. Table- 1 shows the characteristics of 507 patients who included in the study. Conclusion: In spite of no significant difference in follow-up time, serological status (CMV), donor-recipients sex match, bone marrow cell dose(WBC, CD34, MNC), donor type, source of stem cell, graft type, and conditioning regimen, (Busulfan- Oral, Cyclophosphamide, ALG/AIS/ATG, Stoposide)(Table- 1) in both AML and ALL patients, generalized gamma distribution shows that the mean of SBMT in AML patients is 2.52 times of ALL patients. AML ALL Prognostic Factor Death Hazard Function Neoplasms. Tumors. Oncology. Including cancer and carcinogens Kamran Alimoghaddam verfasserin aut Ardeshir Ghavamzadeh verfasserin aut In International Journal of Hematology-Oncology and Stem Cell Research Tehran University of Medical Sciences, 2020 4(2010), 2 (DE-627)688077250 (DE-600)2652853-8 20082207 nnns volume:4 year:2010 number:2 https://doaj.org/article/9ec6998aa0c14cefb1047830d6430628 kostenfrei https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/244 kostenfrei https://doaj.org/toc/2008-2207 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2010 2 |
| allfields_unstemmed |
(DE-627)DOAJ023673206 (DE-599)DOAJ9ec6998aa0c14cefb1047830d6430628 DE-627 ger DE-627 rakwb eng RC254-282 Kourosh Sayehmiri verfasserin aut Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, intensification of therapy by the use of high-dose Cytarabine allogeneic stem cell transplantation in selected cases, paralleled by improvement in supportive care may have contributed to the impotent. In this article we use parametric survival models for recognizing prognostic factors in acute leukemia patients. Patients and methods: Data on patients who underwent bone marrow or peripheral blood transplantation were obtained from the Hematology- Oncology and bone marrow transplantation research center at Shariati hospital, Tehran, Iran. Transplantations were performed between Oct. 17, 1993 to Jan. 31, 2007. Written informed consents for hematopoietic cell collection and transplantation were obtained from patients and donors. The study included patients 2 to 56 years of age who had received either an HLA-matched marrow transplant or a marrow transplant with a single HLA mismatch from an unrelated donor. The mean follow- up period was about 2 years after transplantation. Results: Five hundred and seven patients were included in the study. There were 301 with acute myeloid leukemia (AML) and 206 with acute lymphoblastic leukemia (ALL). The median ages of the AML and ALL patients were 27 (2-55) and 20 years (2-52), respectively. In ALL patients, Prior viral exposure- cytomegalovirus antibody was positive in 143 patients and negative in 30 patients. In AML patients’ Prior viral exposure- cytomegalovirus antibody was positive in 220 patients and negative in 41patients. Table- 1 shows the characteristics of 507 patients who included in the study. Conclusion: In spite of no significant difference in follow-up time, serological status (CMV), donor-recipients sex match, bone marrow cell dose(WBC, CD34, MNC), donor type, source of stem cell, graft type, and conditioning regimen, (Busulfan- Oral, Cyclophosphamide, ALG/AIS/ATG, Stoposide)(Table- 1) in both AML and ALL patients, generalized gamma distribution shows that the mean of SBMT in AML patients is 2.52 times of ALL patients. AML ALL Prognostic Factor Death Hazard Function Neoplasms. Tumors. Oncology. Including cancer and carcinogens Kamran Alimoghaddam verfasserin aut Ardeshir Ghavamzadeh verfasserin aut In International Journal of Hematology-Oncology and Stem Cell Research Tehran University of Medical Sciences, 2020 4(2010), 2 (DE-627)688077250 (DE-600)2652853-8 20082207 nnns volume:4 year:2010 number:2 https://doaj.org/article/9ec6998aa0c14cefb1047830d6430628 kostenfrei https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/244 kostenfrei https://doaj.org/toc/2008-2207 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2010 2 |
| allfieldsGer |
(DE-627)DOAJ023673206 (DE-599)DOAJ9ec6998aa0c14cefb1047830d6430628 DE-627 ger DE-627 rakwb eng RC254-282 Kourosh Sayehmiri verfasserin aut Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, intensification of therapy by the use of high-dose Cytarabine allogeneic stem cell transplantation in selected cases, paralleled by improvement in supportive care may have contributed to the impotent. In this article we use parametric survival models for recognizing prognostic factors in acute leukemia patients. Patients and methods: Data on patients who underwent bone marrow or peripheral blood transplantation were obtained from the Hematology- Oncology and bone marrow transplantation research center at Shariati hospital, Tehran, Iran. Transplantations were performed between Oct. 17, 1993 to Jan. 31, 2007. Written informed consents for hematopoietic cell collection and transplantation were obtained from patients and donors. The study included patients 2 to 56 years of age who had received either an HLA-matched marrow transplant or a marrow transplant with a single HLA mismatch from an unrelated donor. The mean follow- up period was about 2 years after transplantation. Results: Five hundred and seven patients were included in the study. There were 301 with acute myeloid leukemia (AML) and 206 with acute lymphoblastic leukemia (ALL). The median ages of the AML and ALL patients were 27 (2-55) and 20 years (2-52), respectively. In ALL patients, Prior viral exposure- cytomegalovirus antibody was positive in 143 patients and negative in 30 patients. In AML patients’ Prior viral exposure- cytomegalovirus antibody was positive in 220 patients and negative in 41patients. Table- 1 shows the characteristics of 507 patients who included in the study. Conclusion: In spite of no significant difference in follow-up time, serological status (CMV), donor-recipients sex match, bone marrow cell dose(WBC, CD34, MNC), donor type, source of stem cell, graft type, and conditioning regimen, (Busulfan- Oral, Cyclophosphamide, ALG/AIS/ATG, Stoposide)(Table- 1) in both AML and ALL patients, generalized gamma distribution shows that the mean of SBMT in AML patients is 2.52 times of ALL patients. AML ALL Prognostic Factor Death Hazard Function Neoplasms. Tumors. Oncology. Including cancer and carcinogens Kamran Alimoghaddam verfasserin aut Ardeshir Ghavamzadeh verfasserin aut In International Journal of Hematology-Oncology and Stem Cell Research Tehran University of Medical Sciences, 2020 4(2010), 2 (DE-627)688077250 (DE-600)2652853-8 20082207 nnns volume:4 year:2010 number:2 https://doaj.org/article/9ec6998aa0c14cefb1047830d6430628 kostenfrei https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/244 kostenfrei https://doaj.org/toc/2008-2207 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2010 2 |
| allfieldsSound |
(DE-627)DOAJ023673206 (DE-599)DOAJ9ec6998aa0c14cefb1047830d6430628 DE-627 ger DE-627 rakwb eng RC254-282 Kourosh Sayehmiri verfasserin aut Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, intensification of therapy by the use of high-dose Cytarabine allogeneic stem cell transplantation in selected cases, paralleled by improvement in supportive care may have contributed to the impotent. In this article we use parametric survival models for recognizing prognostic factors in acute leukemia patients. Patients and methods: Data on patients who underwent bone marrow or peripheral blood transplantation were obtained from the Hematology- Oncology and bone marrow transplantation research center at Shariati hospital, Tehran, Iran. Transplantations were performed between Oct. 17, 1993 to Jan. 31, 2007. Written informed consents for hematopoietic cell collection and transplantation were obtained from patients and donors. The study included patients 2 to 56 years of age who had received either an HLA-matched marrow transplant or a marrow transplant with a single HLA mismatch from an unrelated donor. The mean follow- up period was about 2 years after transplantation. Results: Five hundred and seven patients were included in the study. There were 301 with acute myeloid leukemia (AML) and 206 with acute lymphoblastic leukemia (ALL). The median ages of the AML and ALL patients were 27 (2-55) and 20 years (2-52), respectively. In ALL patients, Prior viral exposure- cytomegalovirus antibody was positive in 143 patients and negative in 30 patients. In AML patients’ Prior viral exposure- cytomegalovirus antibody was positive in 220 patients and negative in 41patients. Table- 1 shows the characteristics of 507 patients who included in the study. Conclusion: In spite of no significant difference in follow-up time, serological status (CMV), donor-recipients sex match, bone marrow cell dose(WBC, CD34, MNC), donor type, source of stem cell, graft type, and conditioning regimen, (Busulfan- Oral, Cyclophosphamide, ALG/AIS/ATG, Stoposide)(Table- 1) in both AML and ALL patients, generalized gamma distribution shows that the mean of SBMT in AML patients is 2.52 times of ALL patients. AML ALL Prognostic Factor Death Hazard Function Neoplasms. Tumors. Oncology. Including cancer and carcinogens Kamran Alimoghaddam verfasserin aut Ardeshir Ghavamzadeh verfasserin aut In International Journal of Hematology-Oncology and Stem Cell Research Tehran University of Medical Sciences, 2020 4(2010), 2 (DE-627)688077250 (DE-600)2652853-8 20082207 nnns volume:4 year:2010 number:2 https://doaj.org/article/9ec6998aa0c14cefb1047830d6430628 kostenfrei https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/244 kostenfrei https://doaj.org/toc/2008-2207 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2010 2 |
| language |
English |
| source |
In International Journal of Hematology-Oncology and Stem Cell Research 4(2010), 2 volume:4 year:2010 number:2 |
| sourceStr |
In International Journal of Hematology-Oncology and Stem Cell Research 4(2010), 2 volume:4 year:2010 number:2 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
AML ALL Prognostic Factor Death Hazard Function Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| isfreeaccess_bool |
true |
| container_title |
International Journal of Hematology-Oncology and Stem Cell Research |
| authorswithroles_txt_mv |
Kourosh Sayehmiri @@aut@@ Kamran Alimoghaddam @@aut@@ Ardeshir Ghavamzadeh @@aut@@ |
| publishDateDaySort_date |
2010-01-01T00:00:00Z |
| hierarchy_top_id |
688077250 |
| id |
DOAJ023673206 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ023673206</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307065856.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2010 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ023673206</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9ec6998aa0c14cefb1047830d6430628</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Kourosh Sayehmiri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2010</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, intensification of therapy by the use of high-dose Cytarabine allogeneic stem cell transplantation in selected cases, paralleled by improvement in supportive care may have contributed to the impotent. In this article we use parametric survival models for recognizing prognostic factors in acute leukemia patients. Patients and methods: Data on patients who underwent bone marrow or peripheral blood transplantation were obtained from the Hematology- Oncology and bone marrow transplantation research center at Shariati hospital, Tehran, Iran. Transplantations were performed between Oct. 17, 1993 to Jan. 31, 2007. Written informed consents for hematopoietic cell collection and transplantation were obtained from patients and donors. The study included patients 2 to 56 years of age who had received either an HLA-matched marrow transplant or a marrow transplant with a single HLA mismatch from an unrelated donor. The mean follow- up period was about 2 years after transplantation. Results: Five hundred and seven patients were included in the study. There were 301 with acute myeloid leukemia (AML) and 206 with acute lymphoblastic leukemia (ALL). The median ages of the AML and ALL patients were 27 (2-55) and 20 years (2-52), respectively. In ALL patients, Prior viral exposure- cytomegalovirus antibody was positive in 143 patients and negative in 30 patients. In AML patients’ Prior viral exposure- cytomegalovirus antibody was positive in 220 patients and negative in 41patients. Table- 1 shows the characteristics of 507 patients who included in the study. Conclusion: In spite of no significant difference in follow-up time, serological status (CMV), donor-recipients sex match, bone marrow cell dose(WBC, CD34, MNC), donor type, source of stem cell, graft type, and conditioning regimen, (Busulfan- Oral, Cyclophosphamide, ALG/AIS/ATG, Stoposide)(Table- 1) in both AML and ALL patients, generalized gamma distribution shows that the mean of SBMT in AML patients is 2.52 times of ALL patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">AML</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ALL</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognostic Factor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Death Hazard Function</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kamran Alimoghaddam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ardeshir Ghavamzadeh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International Journal of Hematology-Oncology and Stem Cell Research</subfield><subfield code="d">Tehran University of Medical Sciences, 2020</subfield><subfield code="g">4(2010), 2</subfield><subfield code="w">(DE-627)688077250</subfield><subfield code="w">(DE-600)2652853-8</subfield><subfield code="x">20082207</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2010</subfield><subfield code="g">number:2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9ec6998aa0c14cefb1047830d6430628</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/244</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2008-2207</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2010</subfield><subfield code="e">2</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Kourosh Sayehmiri |
| spellingShingle |
Kourosh Sayehmiri misc RC254-282 misc AML misc ALL misc Prognostic Factor misc Death Hazard Function misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation |
| authorStr |
Kourosh Sayehmiri |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)688077250 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC254-282 |
| illustrated |
Not Illustrated |
| issn |
20082207 |
| topic_title |
RC254-282 Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation AML ALL Prognostic Factor Death Hazard Function |
| topic |
misc RC254-282 misc AML misc ALL misc Prognostic Factor misc Death Hazard Function misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_unstemmed |
misc RC254-282 misc AML misc ALL misc Prognostic Factor misc Death Hazard Function misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_browse |
misc RC254-282 misc AML misc ALL misc Prognostic Factor misc Death Hazard Function misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
International Journal of Hematology-Oncology and Stem Cell Research |
| hierarchy_parent_id |
688077250 |
| hierarchy_top_title |
International Journal of Hematology-Oncology and Stem Cell Research |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)688077250 (DE-600)2652853-8 |
| title |
Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation |
| ctrlnum |
(DE-627)DOAJ023673206 (DE-599)DOAJ9ec6998aa0c14cefb1047830d6430628 |
| title_full |
Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation |
| author_sort |
Kourosh Sayehmiri |
| journal |
International Journal of Hematology-Oncology and Stem Cell Research |
| journalStr |
International Journal of Hematology-Oncology and Stem Cell Research |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2010 |
| contenttype_str_mv |
txt |
| author_browse |
Kourosh Sayehmiri Kamran Alimoghaddam Ardeshir Ghavamzadeh |
| container_volume |
4 |
| class |
RC254-282 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Kourosh Sayehmiri |
| author2-role |
verfasserin |
| title_sort |
comparison of prognostic factors and death hazard function of acute myeloid leukemia (aml) and acute lymphoblastic leukemia (all) patients after bone marrow transplantation |
| callnumber |
RC254-282 |
| title_auth |
Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation |
| abstract |
Introduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, intensification of therapy by the use of high-dose Cytarabine allogeneic stem cell transplantation in selected cases, paralleled by improvement in supportive care may have contributed to the impotent. In this article we use parametric survival models for recognizing prognostic factors in acute leukemia patients. Patients and methods: Data on patients who underwent bone marrow or peripheral blood transplantation were obtained from the Hematology- Oncology and bone marrow transplantation research center at Shariati hospital, Tehran, Iran. Transplantations were performed between Oct. 17, 1993 to Jan. 31, 2007. Written informed consents for hematopoietic cell collection and transplantation were obtained from patients and donors. The study included patients 2 to 56 years of age who had received either an HLA-matched marrow transplant or a marrow transplant with a single HLA mismatch from an unrelated donor. The mean follow- up period was about 2 years after transplantation. Results: Five hundred and seven patients were included in the study. There were 301 with acute myeloid leukemia (AML) and 206 with acute lymphoblastic leukemia (ALL). The median ages of the AML and ALL patients were 27 (2-55) and 20 years (2-52), respectively. In ALL patients, Prior viral exposure- cytomegalovirus antibody was positive in 143 patients and negative in 30 patients. In AML patients’ Prior viral exposure- cytomegalovirus antibody was positive in 220 patients and negative in 41patients. Table- 1 shows the characteristics of 507 patients who included in the study. Conclusion: In spite of no significant difference in follow-up time, serological status (CMV), donor-recipients sex match, bone marrow cell dose(WBC, CD34, MNC), donor type, source of stem cell, graft type, and conditioning regimen, (Busulfan- Oral, Cyclophosphamide, ALG/AIS/ATG, Stoposide)(Table- 1) in both AML and ALL patients, generalized gamma distribution shows that the mean of SBMT in AML patients is 2.52 times of ALL patients. |
| abstractGer |
Introduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, intensification of therapy by the use of high-dose Cytarabine allogeneic stem cell transplantation in selected cases, paralleled by improvement in supportive care may have contributed to the impotent. In this article we use parametric survival models for recognizing prognostic factors in acute leukemia patients. Patients and methods: Data on patients who underwent bone marrow or peripheral blood transplantation were obtained from the Hematology- Oncology and bone marrow transplantation research center at Shariati hospital, Tehran, Iran. Transplantations were performed between Oct. 17, 1993 to Jan. 31, 2007. Written informed consents for hematopoietic cell collection and transplantation were obtained from patients and donors. The study included patients 2 to 56 years of age who had received either an HLA-matched marrow transplant or a marrow transplant with a single HLA mismatch from an unrelated donor. The mean follow- up period was about 2 years after transplantation. Results: Five hundred and seven patients were included in the study. There were 301 with acute myeloid leukemia (AML) and 206 with acute lymphoblastic leukemia (ALL). The median ages of the AML and ALL patients were 27 (2-55) and 20 years (2-52), respectively. In ALL patients, Prior viral exposure- cytomegalovirus antibody was positive in 143 patients and negative in 30 patients. In AML patients’ Prior viral exposure- cytomegalovirus antibody was positive in 220 patients and negative in 41patients. Table- 1 shows the characteristics of 507 patients who included in the study. Conclusion: In spite of no significant difference in follow-up time, serological status (CMV), donor-recipients sex match, bone marrow cell dose(WBC, CD34, MNC), donor type, source of stem cell, graft type, and conditioning regimen, (Busulfan- Oral, Cyclophosphamide, ALG/AIS/ATG, Stoposide)(Table- 1) in both AML and ALL patients, generalized gamma distribution shows that the mean of SBMT in AML patients is 2.52 times of ALL patients. |
| abstract_unstemmed |
Introduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, intensification of therapy by the use of high-dose Cytarabine allogeneic stem cell transplantation in selected cases, paralleled by improvement in supportive care may have contributed to the impotent. In this article we use parametric survival models for recognizing prognostic factors in acute leukemia patients. Patients and methods: Data on patients who underwent bone marrow or peripheral blood transplantation were obtained from the Hematology- Oncology and bone marrow transplantation research center at Shariati hospital, Tehran, Iran. Transplantations were performed between Oct. 17, 1993 to Jan. 31, 2007. Written informed consents for hematopoietic cell collection and transplantation were obtained from patients and donors. The study included patients 2 to 56 years of age who had received either an HLA-matched marrow transplant or a marrow transplant with a single HLA mismatch from an unrelated donor. The mean follow- up period was about 2 years after transplantation. Results: Five hundred and seven patients were included in the study. There were 301 with acute myeloid leukemia (AML) and 206 with acute lymphoblastic leukemia (ALL). The median ages of the AML and ALL patients were 27 (2-55) and 20 years (2-52), respectively. In ALL patients, Prior viral exposure- cytomegalovirus antibody was positive in 143 patients and negative in 30 patients. In AML patients’ Prior viral exposure- cytomegalovirus antibody was positive in 220 patients and negative in 41patients. Table- 1 shows the characteristics of 507 patients who included in the study. Conclusion: In spite of no significant difference in follow-up time, serological status (CMV), donor-recipients sex match, bone marrow cell dose(WBC, CD34, MNC), donor type, source of stem cell, graft type, and conditioning regimen, (Busulfan- Oral, Cyclophosphamide, ALG/AIS/ATG, Stoposide)(Table- 1) in both AML and ALL patients, generalized gamma distribution shows that the mean of SBMT in AML patients is 2.52 times of ALL patients. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
2 |
| title_short |
Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation |
| url |
https://doaj.org/article/9ec6998aa0c14cefb1047830d6430628 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/244 https://doaj.org/toc/2008-2207 |
| remote_bool |
true |
| author2 |
Kamran Alimoghaddam Ardeshir Ghavamzadeh |
| author2Str |
Kamran Alimoghaddam Ardeshir Ghavamzadeh |
| ppnlink |
688077250 |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| callnumber-a |
RC254-282 |
| up_date |
2024-07-03T18:52:23.084Z |
| _version_ |
1803585053619388416 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ023673206</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307065856.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2010 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ023673206</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9ec6998aa0c14cefb1047830d6430628</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Kourosh Sayehmiri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of Prognostic Factors and Death Hazard Function of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients after Bone Marrow Transplantation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2010</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction: The majority of leukemia patients are acute leukemia patients, so that about 70.8% lymphoblastic leukemia were acute lymphoblastic leukemia (ALL) patients and 66.4 % of myeloid leukemia patients were acute myeloid leukemia (AML) in Tehran metropolitan. During the last two decades, intensification of therapy by the use of high-dose Cytarabine allogeneic stem cell transplantation in selected cases, paralleled by improvement in supportive care may have contributed to the impotent. In this article we use parametric survival models for recognizing prognostic factors in acute leukemia patients. Patients and methods: Data on patients who underwent bone marrow or peripheral blood transplantation were obtained from the Hematology- Oncology and bone marrow transplantation research center at Shariati hospital, Tehran, Iran. Transplantations were performed between Oct. 17, 1993 to Jan. 31, 2007. Written informed consents for hematopoietic cell collection and transplantation were obtained from patients and donors. The study included patients 2 to 56 years of age who had received either an HLA-matched marrow transplant or a marrow transplant with a single HLA mismatch from an unrelated donor. The mean follow- up period was about 2 years after transplantation. Results: Five hundred and seven patients were included in the study. There were 301 with acute myeloid leukemia (AML) and 206 with acute lymphoblastic leukemia (ALL). The median ages of the AML and ALL patients were 27 (2-55) and 20 years (2-52), respectively. In ALL patients, Prior viral exposure- cytomegalovirus antibody was positive in 143 patients and negative in 30 patients. In AML patients’ Prior viral exposure- cytomegalovirus antibody was positive in 220 patients and negative in 41patients. Table- 1 shows the characteristics of 507 patients who included in the study. Conclusion: In spite of no significant difference in follow-up time, serological status (CMV), donor-recipients sex match, bone marrow cell dose(WBC, CD34, MNC), donor type, source of stem cell, graft type, and conditioning regimen, (Busulfan- Oral, Cyclophosphamide, ALG/AIS/ATG, Stoposide)(Table- 1) in both AML and ALL patients, generalized gamma distribution shows that the mean of SBMT in AML patients is 2.52 times of ALL patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">AML</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ALL</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognostic Factor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Death Hazard Function</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kamran Alimoghaddam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ardeshir Ghavamzadeh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International Journal of Hematology-Oncology and Stem Cell Research</subfield><subfield code="d">Tehran University of Medical Sciences, 2020</subfield><subfield code="g">4(2010), 2</subfield><subfield code="w">(DE-627)688077250</subfield><subfield code="w">(DE-600)2652853-8</subfield><subfield code="x">20082207</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2010</subfield><subfield code="g">number:2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9ec6998aa0c14cefb1047830d6430628</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/244</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2008-2207</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2010</subfield><subfield code="e">2</subfield></datafield></record></collection>
|
| score |
7.3978233 |